Skip to Main content Skip to Navigation
Journal articles

Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society

C. Lebrun 1 S. Vukusic 2, 3, * V. Abadie C. Achour F. Ader 4 H. Alchaar A. Alkhedr F. Andreux 5 G. Androdias R. Arjmand Bertrand Audoin 6 D. Audry D. Aufauvre C. Autreaux X. Ayrignac 7 M. Bailbe M. Benazet C. Bensa D. Bensmail Eric Berger P. Bernady Y. Bertagna D. Biotti A. Blanchard-Dauphin J. Bonenfant 8 M. Bonnan B. Bonnemain F. Borgel E. Botelho-Nevers 9 S. Boucly Bertrand Bourre C. Boutière 10 P. Branger D. Brassat 6 S. Bresch 11 V. Breuil 12 Bruno Brochet 6 H. Brugeilles P. Bugnon Philippe Cabre Jean-Philippe Camdessanché C. Carra-Dalière Olivier Casez J.-M. Chamouard B. Chassande P. Chataignier M. Chbicheb A. Chenet 13 Jonathan Ciron Pierre Clavelou 6 M. Cohen 14 R. Colamarino N. Collongues 6 I. Coman P.-R. Corail S. Courtois M. Coustans 15 Alain Créange 16 E. Creisson N. Daluzeau C. Davenas J. de Seze 6 Marc Debouverie 17 R. Depaz N. Derache L. Divio X. Douay C. Dulau F. Durand-Dubief 18 G. Edan 15 Z. Elias O. Fagniez M. Faucher J.-M. Faucheux M. Fournier 19 A. Gagneux-Brunon 9 P. Gaida P. Galli P. Gallien J. Gaudelus 20 D. Gault 21 A. Gayou M. Genevray A. Gentil J. Gere L. Gignoux M. Giroux P. Givron O. Gout 22 J. Grimaud A.-M. Guennoc N. Hadhoum P. Hautecoeur Olivier Heinzlef M. Jaeger 23 S. Jeannin L. Kremer 24 A. Kwiatkowski Pierre Labauge 6 Céline Labeyrie S. Lachaud I. Laffont 25 C. Lanctin-Garcia J. Lannoy L. Lanotte David Laplaud 26 D. Latombe M. Lauxerois E. Le Page 8 Christine Lebrun-Frenay 27 P. Lejeune P. Lejoyeux B. Lemonnier Emmanuelle Leray 28, 29, 30 C.-M. Loche C. Louapre 31 Catherine Lubetzki 32 A. Maarouf 6 B. Mada L. Magy 6 E. Maillart 33 E. Manchon R. Marignier 3 P. Marque G. Mathey 17 A. Maurousset C. Mekies M. Merienne 24 L. Michel A.-M. Milor X. Moisset 34 Alexis Montcuquet Thibault Moreau N. Morel M. Moussa J.-P. Naudillon M. Normand P. Olive J.-C. Ouallet Olivier Outteryck C. Pacault C. Papeix 33 Ivania Patry 35 D. Peaureaux Jean Pelletier 36 B. Pichon 37 S. Pittion E. Planque M.-C. Pouget V. Pourcher 38 C. Radot I. Robert F. Rocher A. Ruet 39 C. Saint-Val J.-Y. Salle A. Salmon E. Sartori S. Schaeffer B. Stankhof F. Taithe 40 Eric Thouvenot 6 C. Tizon Ayman Tourbah 41 P. Tourniaire M. Vaillant 42 Patrick Vermersch 6 S. Vidil A. Wahab M.-H. Warter S. Wiertlewski 43 B. Wiplosz B. Wittwer C. Zaenker H. Zephir 6
* Corresponding author
18 RMN et optique : De la mesure au biomarqueur
CREATIS - Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé
Abstract : Objectives: To establish recommendations on immunization for patients with multiple sclerosis (MS).Background: Vaccines have been suspected in the past to trigger MS and relapses. With the extension of the immunoactive treatment arsenal, other concerns have been raised more recently about an increased risk of infection or a decreased effectiveness of immunization in immunosuppressed patients.Methods: The French Group for Recommendations into Multiple Sclerosis (France4MS) performed a systematic search of papers in Medline and other university databases (January 1975-June 2018). The RAND/UCLA appropriateness method was chosen to review the scientific literature and to formalize the degree of agreement among experts on 5 clinical questions related to immunization and MS. Readers from the steering committee conducted a systematic analysis, wrote a critical synthesis and prepared a list of proposals that were evaluated by a rating group of 28 MS experts. The final version of the recommendations was finally reviewed by a reading group of 110 health care professionals and classified as appropriate, inappropriate or uncertain.Results: Neurologists should verify the vaccination status as soon as MS is diagnosed and before disease-modifying treatments (DMTs) are introduced. The French vaccination schedule applies to MS patients and seasonal influenza vaccination is recommended. In the case of treatment-induced immunosuppression, MS patients should be informed about the risk of infection and the vaccination standards of the French High Council of Health should be applied. Live attenuated vaccines are contra-indicated in patients recently treated with immunosuppressive drugs, including corticosteroids; other vaccines can be proposed whatever the treatment, but their effectiveness may be partly reduced with some drugs.Conclusion: Physicians and patients should be aware of the updated recommendations for immunizations of patients with MS.
Document type :
Journal articles
Complete list of metadata

https://hal.ehesp.fr/hal-02546158
Contributor : Scd Ehesp Connect in order to contact the contributor
Submitted on : Friday, April 17, 2020 - 5:14:19 PM
Last modification on : Friday, December 3, 2021 - 12:13:18 PM

Links full text

Identifiers

Citation

C. Lebrun, S. Vukusic, V. Abadie, C. Achour, F. Ader, et al.. Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. Revue Neurologique, Elsevier Masson, 2019, 175 (6), pp.341-357. ⟨10.1016/j.neurol.2019.04.001⟩. ⟨hal-02546158⟩

Share

Metrics

Record views

557